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Objective: Acute limb ischemia remains one of the most challenging emergencies in vascular surgery. Historically,
outcomes following interventions for acute limb ischemia have been associated with high rates of morbidity and
mortality. The purpose of this study was to determine contemporary outcomes following lower extremity bypass per-
formed for acute limb ischemia.
Methods: All patients undergoing infrainguinal lower extremity bypass between 2003 and 2011 within hospitals
comprising the Vascular Study Group of New England were identiﬁed. Patients were stratiﬁed according to whether or
not the indication for lower extremity bypass was acute limb ischemia. Primary end points included bypass graft occlu-
sion, major amputation, and mortality at 1 year postoperatively as determined by Kaplan-Meier life table analysis.
Multivariable Cox proportional hazards models were constructed to evaluate independent predictors of mortality and
major amputation at 1 year.
Results: Of 5712 lower extremity bypass procedures, 323 (5.7%) were performed for acute limb ischemia. Patients
undergoing lower extremity bypass for acute limb ischemia were similar in age (66 vs 67; P[ .084) and sex (68% male vs
69% male; P [ .617) compared with chronic ischemia patients, but were less likely to be on aspirin (63% vs 75%; P <
.0001) or a statin (55% vs 68%; P < .0001). Patients with acute limb ischemia were more likely to be current smokers (49%
vs 39%; P < .0001), to have had a prior ipsilateral bypass (33% vs 24%; P [ .004) or a prior ipsilateral percutaneous
intervention (41% vs 29%; P [ .001). Bypasses performed for acute limb ischemia were longer in duration (270 vs 244
minutes; P[ .007), had greater blood loss (363 vs 272 mL; P < .0001), and more commonly utilized prosthetic conduits
(41% vs 33%; P [ .003). Acute limb ischemia patients experienced increased in-hospital major adverse events (20% vs
12%; P < .0001) including myocardial infarction, congestive heart failure exacerbation, deterioration in renal function,
and respiratory complications. Patients who underwent lower extremity bypass for acute limb ischemia had no difference
in rates of graft occlusion (18.1% vs 18.5%; P[ .77), but did have signiﬁcantly higher rates of limb loss (22.4% vs 9.7%;
P < .0001) and mortality (20.9% vs 13.1%; P < .0001) at 1 year. On multivariable analysis, acute limb ischemia was an
independent predictor of both major amputation (hazard ratio, 2.16; conﬁdence interval, 1.38-3.40; P [ .001) and
mortality (hazard ratio, 1.41; conﬁdence interval, 1.09-1.83; P [ .009) at 1 year.
Conclusions: Patients who present with acute limb ischemia represent a less medically optimized subgroup within the
population of patients undergoing lower extremity bypass. These patients may be expected to have more complex
operations followed by increased rates of perioperative adverse events. Additionally, despite equivalent graft patency rates,
patients undergoing lower extremity bypass for acute ischemia have signiﬁcantly higher rates of major amputation and
mortality at 1 year. (J Vasc Surg 2013;58:949-56.)Acute lower extremity ischemia resulting from arterial
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limb loss have traditionally been reported to be as high as
20%-40% and 12%-50%, respectively.1-6 Conventional
treatment of patients with acute lower extremity ischemia
has been systemic anticoagulation and emergent open
surgical intervention, speciﬁcally thromboembolectomy or
bypass. However, the therapeutic approach to patients pre-
senting with acute lower extremity ischemia underwent
a transformation in the mid-1990s with the advent of
endovascular therapy, and more speciﬁcally, the use of
catheter-directed thrombolysis. As reported in several
randomized controlled trials,7-12 this endovascular
approach offers a less invasive approach to conventional
surgical revascularization but often requires more time to
restore arterial ﬂow, can be associated with higher rates
of hemorrhage, and has not been shown deﬁnitively to
improve limb salvage. Despite advances in endovascular
techniques and equipment,13-15 along with improvements949
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proportion of patients presenting with acute lower
extremity ischemia still require urgent surgical bypass for
limb salvage.
The characteristics of patients who present with acute
lower extremity ischemia remain ill-deﬁned, particularly
in the setting of contemporary application of both elective
endovascular and surgical interventions for peripheral
vascular disease. Such patients may represent a subgroup
of patients with peripheral vascular disease who have
more advanced disease or may not be medically optimized,
placing them at risk for acute events. The purpose of this
study was to utilize data from the prospectively collected
Vascular Study Group of New England (VSGNE) database
to better characterize the acute lower extremity ischemia
patient population and to determine outcomes following
lower extremity bypass performed for acute lower
extremity ischemia. We hypothesized that patients under-
going lower extremity bypass for acute ischemia represent
a less medically optimized subgroup of patients with
peripheral vascular disease who are at higher risk for peri-
operative adverse events and worse outcomes at 1 year.
METHODS
Study design and database. This study was a retro-
spective analysis of patients undergoing infrainguinal lower
extremity bypass between January 1, 2003 and December
31, 2011 at all 30 centers that participate in the VSGNE.
The VSGNE is a regional cooperative quality improvement
initiative developed by community and academic centers in
New England in 2002 to evaluate regional outcomes in
vascular surgery. Details regarding this registry have been
previously published and are available at www.vsgne.
org.16 All data are self-reported and sent to a central data
repository where it is aggregated and reviewed.
Data are collected at the time of the initial operation,
including preoperative, intraoperative, and postoperative
information. Follow-up data are then collected at 1 year.
One-year data collected includes ambulation status,
symptom status, graft patency, ankle-brachial index, need
for graft revisions, and amputations. Vital status is entered
directly into the database and matched to the Social Secu-
rity Death Index.
Deﬁnitions. Patient information for more than 100
clinical and demographic variables was collected (complete
list available at www.vsgne.org). Speciﬁc comborbidities
examined included coronary artery disease (CAD, prior
myocardial infarction, or angina), chronic obstructive
pulmonary disease (medication-dependent or home
oxygen-dependent), congestive heart failure (CHF, by
history), diabetes mellitus (insulin-dependent diabetes
mellitus or noninsulin-dependent diabetes mellitus, con-
trolled by oral medication or diet), hypertension (history of
hypertension or blood pressure $140/90 mm Hg on the
preoperative evaluation), and history of tobacco use
(never, <1 year prior, or current). Renal disease was clas-
siﬁed as normal (serum creatinine #1.8 mg/dL), renal
insufﬁciency (serum creatinine >1.8 mg/dL), or dialysis-dependent. Relevant surgical history is also obtained at
the time of initial operation, including prior ipsilateral and
contralateral endovascular and open revascularizations
along with prior ipsilateral and contralateral amputations.
Indications for bypass are classiﬁed as asymptomatic,
claudication, rest pain, tissue loss, and acute ischemia.
Urgency of bypass is speciﬁed as elective, urgent, or emer-
gent. Pathology treated is identiﬁed as occlusive or aneu-
rysm. Patients were included in the study group if the
indication for bypass was acute ischemia and the urgency
was either urgent or emergent. The study group as deﬁned
here was subsequently compared with all other patients
undergoing infrainguinal lower extremity bypass.
Immediate postoperative data relating to major in-
hospital adverse events including the occurrence of
myocardial infarction, dysrhythmia, CHF, change in renal
function, respiratory complications, and stroke are
recorded. Long-term follow-up data included vital status,
graft patency, and amputation status. Graft patency is
determined at 1 year by the practitioners via one of the
following methods: Doppler examination, palpable graft
pulse, palpable distal pulse, ankle-brachial index increase
>0.15 from preoperative value, or duplex. Postoperative
graft surveillance is not standardized across institutions.
Study end points. The primary study end points were
bypass graft occlusion, major amputation, and mortality at
1 year postoperatively. Secondary end points included in-
hospital major adverse events (speciﬁcally myocardial
infarction, dysrhythmia, CHF, change in renal function,
and respiratory complications), along with freedom
from major adverse limb events (combined end point of
major amputation, new bypass graft, graft revision, or
thrombectomy/thrombolysis of bypass) at 1 year and
amputation-free survival at 1 year.
Statistical analysis. Baseline characteristics were
compared between groups using Pearson c2 analysis for
categorical variables and the t-test for continuous variables.
Kaplan-Meier life table analyses were used to calculate all
time-to-event end points. Intergroup differences were
evaluated using the log rank test. Cox proportional hazards
models were constructed to determine independent
predictors of major amputation, graft occlusion, and
mortality at 1 year. Variables with P < .2 in univariate
analysis were included in a backward stepwise selection
multivariable analysis. Covariates with P < .05 were
included in the ﬁnal model. All software analyses were per-
formed using SAS 9.1 software (SAS Institute, Cary, NC).
RESULTS
Cohort characteristics. Three hundred twenty-three
(5.7%) of 5712 lower extremity bypasses were performed
for the indication acute limb ischemia and classiﬁed as an
emergent or urgent procedure. Speciﬁcally, 64% of these
bypasses were documented as urgent and 36% as emergent.
When compared with those patients undergoing lower
extremity bypass for all other indications, this population
was no different in age or sex distribution (Table I).
Additionally, there were no differences in the rates of CAD,
Table I. Patient demographics
Variable
Bypass performed
for acute limb
ischemia
(n ¼ 323)
All other
bypasses
(n ¼ 5389)
P
value
Age, mean, years 66.3 67.4 .084
Male sex, % 67.8 69.1 .617
CAD, % 30.3 35.7 .051
CHF, % 13.9 15.7 .393
COPD, % 32.2 26.2 .017
Diabetes, %
NIDDM 18.0 25.3 <.001
IDDM 18.9 25.2 <.001
Hypertension, % 81.4 86.5 .010
Renal insufﬁciency, % 13.9 13.1 .687
Hemodialysis, % 5.3 6.0 .193
Current tobacco use, % 48.5 39.4 <.001
Beta-blocker usage, % 71.1 76.7 .023
Aspirin usage, % 62.5 74.8 <.001
Statin usage, % 54.8 68.1 <.001
Prior ipsilateral bypass, % 32.8 23.5 .004
Prior ipsilateral percutaneous
intervention, %
41.1 28.8 <.001
Aneurysm as indication, % 14.0 6.8 <.001
CAD, Coronary artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; IDDM, insulin-dependent diabetes
mellitus; NIDDM, noninsulin-dependent diabetes mellitus.
Table II. Perioperative major adverse events
Variable
Bypass performed
for acute limb
ischemia (n ¼ 323)
All other
bypasses
(n ¼ 5389)
P
value
Any in-hospital major
adverse event, %
19.8 11.6 <.0001
Myocardial
infarction, %
7.5 3.6 .001
Dysrhythmia, % 4.4 4.0 .727
CHF, % 5.6 3.3 .028
Deterioration in renal
function, %
6.6 4.4 .001
Respiratory, % 3.7 1.4 .004
CHF, Congestive heart failure.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 4 Baril et al 951CHF, renal insufﬁciency, or hemodialysis dependence
between the two groups. However, patients undergoing
lower extremity bypass for acute ischemia had a higher
incidence of chronic obstructive pulmonary disease but
a lower incidence of diabetes and hypertension. Further-
more, patients undergoing lower extremity bypass for acute
ischemia were more likely to be current smokers, and less
likely to be taking a beta-blocker, an aspirin, or a statin.
Patients undergoing lower extremity bypass for acute
ischemia were more likely to have had undergone a previous
ipsilateral endovascular intervention than those undergoing
bypass for all other indications (41.1% vs 28.8%; P < .001).
Additionally, these patients were more likely to have under-
gone a prior ipsilateral bypass (32.8% vs 23.5%; P ¼ .004).
Aneurysm as the indication for bypass was more frequent
for the acute ischemia group (14.0% vs 6.8%; P < .001).
Intraoperative differences were noted between the two
groups. Speciﬁcally, patients undergoing lower extremity
bypass for acute ischemia had longer operative times than
those undergoing lower extremity bypass for all other indi-
cations (270 minutes vs 244 minutes; P ¼ .007). These
procedures were associated with higher rates of blood
loss (363 vs 272 mL; P < .001) and more common use
of prosthetic conduit (40.6% vs 32.6%; P ¼ .003). There
were no differences seen in the rates of tibial targets
(42.4% vs 38.0%; P ¼ .110) between the groups but the
use of completion imaging studies was less frequent in
the acute ischemia group (46.8% vs 53.7%; P ¼ .039).
Perioperative major adverse events. Patients under-
going lower extremity bypass for acute ischemia experi-
enced an increased rate of in-hospital major adverseevents compared with those undergoing bypass for all
other indications (19.8% vs 11.6%; P < .0001). Speciﬁcally,
these patients had higher rates of postoperative myocardial
infarctions (7.5% vs 3.6%; P ¼ .001), CHF exacerbations
(5.6% vs 3.3%; P ¼ .028), deterioration in renal function
(6.6% vs 4.4%; P ¼ .001), and respiratory complications
(3.7% vs 1.4%; P ¼ .004) (Table II).
In addition to these medical adverse events, patients
undergoing lower extremity bypass for acute ischemia
were more likely to return to the operating room
(including for amputation) during their hospitalization
than those undergoing bypass for all other indications
(23.7% vs 11.2%; P < .0001).
One-year outcomes. Although patients undergoing
lower extremity bypass for acute ischemia experienced no
difference in rates of graft occlusion at 1 year compared
with patients undergoing bypass for all other indications
(18.1% vs 18.5%; P ¼ .77) (Fig 1), these patients did
experience higher rates of both major amputation (22.4%
vs 9.7%; P < .0001) and mortality at 1 year (20.9% vs
13.1%; P < .0001) (Figs 2 and 3). As a result, amputation-
free survival at 1 year was signiﬁcantly lower for patients
undergoing lower extremity bypass for acute ischemia
compared with patients undergoing bypass for all other
indications (62.8% vs 77.4%; P < .0001) (Fig 4). Freedom
from major adverse limb events was lower in patients
undergoing lower extremity bypass for acute ischemia
(60.4% vs 66.7%; P < .0001). Of the patients undergoing
lower extremity bypass for acute ischemia with pathology
classiﬁed as aneurysm, the 1-year major amputation rate
was 13.6% and the 1-year mortality was 20%.
Multivariable analysis. Acute ischemia was an inde-
pendent predictor of both amputation (hazard ratio, 2.16;
conﬁdence interval, 1.38-3.40; P < .0001) (Table III)
and mortality at 1 year (hazard ratio, 1.41; conﬁdence
interval, 1.09-1.83; P ¼ .0009) (Table IV) on multivariable
analysis.
DISCUSSION
Despite advances in preventative care along with the
increased treatment of both peripheral arterial disease and
cardiac dysrhythmias, a signiﬁcant number of patients
Fig 1. Freedom from graft occlusion.
Fig 2. Freedom from major amputation.
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These patients most often require urgent intervention
and have been traditionally thought to be at high risk for
both limb loss and death. Therapeutic options include
endovascular approaches, most commonly with the use of
thrombolytic therapy, surgical approaches including
thromboembolectomy and bypass, and primary amputa-
tion. Although clinical experience and anecdote might
suggest that patients requiring urgent or emergent surgical
revascularization will fare worse than their elective counter-
parts, these outcomes have not been rigorously compared.
This study demonstrates that patients with acute lower
extremity ischemia who undergo lower extremity bypass,
when compared with patients undergoing elective bypass,
represent a distinct group who are at higher risk for both
perioperative adverse events and worse outcomes, speciﬁ-
cally mortality and limb loss, at 1 year.Although a variety of risk factors predisposing patients
to the development of acute lower extremity ischemia have
been identiﬁed, including peripheral arterial disease, atrial
ﬁbrillation, and known hypercoagulable disorders, the
characteristics of those patients undergoing lower ex-
tremity bypass for acute ischemia remain ill-deﬁned.
Patients in this study who presented with acute lower
extremity ischemia requiring surgical bypass represented
a less medically optimized group of patients when
compared with those undergoing elective bypass. While
the incidence of multiple medical comorbidities including
CAD, CHF, and renal insufﬁciency were no different
between the two groups, there were signiﬁcantly more
active tobacco users in the acute lower extremity ischemia
group along with signiﬁcantly fewer patients on aspirin,
beta-blockers, and statins. These lower rates of cardiopro-
tective medication utilization likely not only placed these
Fig 3. Survival.
Fig 4. Amputation-free survival.
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predisposed these patients to higher rates of perioperative
adverse events. The effect of statin use speciﬁcally has
been studied previously for patients with lower extremity
atherosclerotic disease undergoing elective surgery and
has been shown to be associated with decreased periopera-
tive cardiac complications17 along with improved graft
patency and limb salvage18 and 1-year postoperative
survival.19 Consistent with these ﬁndings, our multivariable
analysis of predictors of 1-year mortality identiﬁed statin
use as protective.
In addition to the differences in medical characteristics
between patients undergoing bypass for acute lower
extremity ischemia and those undergoing elective bypass,
there were also signiﬁcant differences in the rates of both
prior ipsilateral bypasses and prior ipsilateral peripheral
vascular interventions. Nearly one-third of patients in the
acute lower extremity ischemia group had a prior ipsilateralbypass, and over 40% had undergone a prior ipsilateral
peripheral vascular intervention. Previously VSGNE inves-
tigators, Bypass versus Angioplasty in Severe Ischaemia of
the Leg (BASIL) trial study investigators, and others
have demonstrated that failed percutaneous interventions
lead to worse outcomes after subsequent bypass with lower
rates of limb salvage.20-22 However, to date, the need for
acute intervention at the time of percutaneous intervention
failure has not been well reported. Although it is not
possible to determine the denominator of patients under-
going prior percutaneous intervention in this dataset, it is
evident that at the time of failure, a signiﬁcant proportion
will present acutely and require urgent intervention,
including the need for surgical bypass. When compared
with elective bypass, patients requiring bypass for acute
lower extremity ischemia are subject to longer operations
with greater blood loss and the more frequent use of pros-
thetic conduit. The role of previous interventions, both
Table III. Independent predictors of amputation at 1
year
HR 95% CI P value
NIDDM 1.56 1.09-2.24 .016
IDDM 1.98 1.44-2.74 <.0001
Prosthetic conduit 2.03 1.51-2.72 <.0001
Prior ipsilateral percutaneous
intervention
2.08 1.23-3.53 .007
Acute ischemia 2.16 1.38-3.40 <.0001
Tibial target vessel 2.75 2.05-3.69 <.0001
CI, Conﬁdence interval; HR, hazard ratio; IDDM, insulin-dependent dia-
betes mellitus; NIDDM, noninsulin-dependent diabetes mellitus.
Table IV. Independent predictors of mortality at 1 year
HR 95% CI P value
Statin therapy 0.80 0.71-0.91 .0007
Tibial target 1.15 1.01-1.32 .036
CAD 1.19 1.05-1.36 .009
IDDM 1.26 1.08-1.48 .004
NIDDM 1.29 1.10-1.51 .029
Prosthetic conduit 1.30 1.13-1.49 .0002
Acute ischemia 1.41 1.09-1.83 .009
COPD 1.46 1.28-1.67 <.0001
Renal insufﬁciency 1.58 1.36-1.83 <.0001
CHF 1.63 1.41-1.89 <.0001
Perioperative major adverse event 1.73 1.48-2.02 <.0001
CAD, Coronary artery disease; CHF, congestive heart failure; CI, conﬁ-
dence interval; COPD, chronic obstructive pulmonary disease; HR, hazard
ratio; IDDM, insulin-dependent diabetes mellitus; NIDDM, noninsulin-
dependent diabetes mellitus.
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increased complexity of such urgent bypasses and their
subsequent inferior outcomes.
Given the patient characteristics along with the in-
creased operative time and blood loss, it is not unexpected
that patients undergoing lower extremity bypass for acute
ischemia are at higher risk for perioperative major adverse
events. In this study, patients undergoing lower extremity
bypass for acute ischemia had a nearly 20% rate of major
adverse perioperative adverse events including a twofold
higher incidence of myocardial infarction compared with
elective bypass patients. Additionally, these patients were
twice as likely to return to the operating room during their
initial admission. Unfortunately, patients with acute lower
extremity ischemia most often necessitate urgent interven-
tion and many may lack any revascularization option aside
from surgical bypass. Accordingly, the ability to medically
optimize these patients preoperatively is relatively limited.
However, these rates of in-hospital adverse events should
prompt the use of strict adherence to the best medical
management in the perioperative period.
Along with inferior perioperative outcomes, patients
undergoing bypass for acute lower extremity ischemia
had inferior outcomes at 1 year, speciﬁcally mortality and
limb loss, despite no differences in rates of graft secondarypatency compared with patients who underwent bypass for
all other indications. Although not all of the anatomic
factors are known for these patients, speciﬁcally the status
of their runoff, it is evident that a signiﬁcant number of
patients undergoing bypass for acute lower extremity
ischemia will require a major amputation in the setting of
a patent bypass. Previously, in a review of nearly 900
patients with thrombosed popliteal artery aneurysms, it
has been shown that the adjunctive use of thrombolysis
improves graft patency rates but does not reduce the
number of amputations, demonstrating that improving
patency does not equate to limb salvage in the setting of
acute lower extremity ischemia.23 An additional factor
that likely contributes to limb loss is the extent of irrevers-
ible muscle damage at the time of revascularization neces-
sitating amputation despite adequate revascularization. In
review of the Kaplan-Meier curves for amputation, it is
evident that the majority of the amputations occur rela-
tively early following surgery as the curves are parallel
beyond the ﬁrst few postoperative months.
In a previous review of factors associated with death
after lower extremity bypass in the VSGNE database, emer-
gent nature of the procedure was the strongest predictor
of death at 1 year with a hazard ratio of 3.4.24 In this
review, acute lower extremity ischemia was an independent
predictor of 1-year mortality as well. Furthermore, the
occurrence of a perioperative adverse event was also
a predictor of 1-year mortality, which patients with acute
lower extremity ischemia suffered from at signiﬁcantly
higher rates than other patients. As with the amputations,
the Kaplan-Meier curves for survival are parallel beyond
the early postoperative period, indicative that the worse
1-year outcomes for patients with acute limb ischemia
stem from their initial postoperative courses.
Unfortunately, the VSGNE database cannot be used to
make any direct comparisons between the outcomes of
patients with acute limb ischemia treated with endovascular
interventions vs those treated with surgical bypass. Data on
peripheral interventions only began being collected by
the VSGNE in 2011, and they have not yet been validated
and released for analysis. Taken in aggregate, the earlier
randomized trials that attempted to address this speciﬁc
comparative effectiveness question demonstrated that
endovascular intervention could be beneﬁcial in certain
clinical settings such as thrombosis (as opposed to embo-
lization) in a limb without motor and sensory compro-
mise.7-11 As these studies are now 15 years old, further
work is necessary to better understand which patient sub-
groups might beneﬁt more from an endovascular approach
compared with an open surgical bypass. However, it remains
apparent that surgical intervention in these patients
continues to be associated with poor outcomes at 1 year.
The primary limitation of this study was its retrospec-
tive nature. An additional limitation is that this study is
reporting only on outcomes following surgical bypass and
does not include patients with acute limb ischemia who
were treated with either thromboembolectomy alone or
with endovascular techniques. While data in the VSGNE
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a retrospective fashion. Despite the breadth and detail of
the information, which is obtained at the time of lower
extremity bypass, certain patient factors are not captured.
Speciﬁcally relevant to this study is the lack of information
regarding the exact etiology of the acute ischemia.
Although pathology is differentiated between aneurysmal
disease and occlusive disease, there is no means of deter-
mining whether the occlusive disease is due to an embolic
or a thrombotic event. However, in each case, the
pathology did require surgical bypass. There is, however,
no means of determining if patients in this cohort under-
went attempts at thrombolytic therapy or surgical throm-
boembolectomy immediately prior to their surgical
intervention. Furthermore, the presence of a documented
hypercoagulable state is not captured nor is a history of
atrial ﬁbrillation, both of which would be of relevance to
this patient population. Additionally, the data are self-
reported, which may lead to observer bias. VSGNE data
are collected from multiple institutions and multiple
surgeons within those institutions, and, as such, postoper-
ative surveillance protocols may differ, which may also
contribute to disparate outcomes.
Despite these important limitations, it is important to
recognize that the VSGNE has successfully collected data
with very high accuracy and that these data have been vali-
dated with regularly scheduled audits.16 These data are
generalizable secondary to the diversity of the practitioners
and hospitals participating in this quality improvement
registry. This report is the largest study to date describing
the characteristics of patients undergoing lower extremity
bypass for acute limb ischemia and documenting the in-
hospital and 1-year outcomes that can be anticipated in
this setting.
CONCLUSIONS
Lower extremity bypass remains an important tool
among the treatment options for patients presenting with
acute ischemia despite advances in endovascular therapy.
Of patients undergoing lower extremity bypass, patients
who present with acute ischemia represent a less medically
optimized subgroup that often have had a failed prior
endovascular or surgical intervention and can be expected
to require longer operations with higher associated blood
losses. Postoperatively, these patients will have increased
rates of in-hospital perioperative adverse events. Addition-
ally, despite equivalent graft patency rates, patients under-
going lower extremity bypass for acute limb ischemia have
signiﬁcantly higher rates of amputation and mortality at 1
year. Although treatment for these patients most often
cannot be delayed or altered, these outcomes should be
factored into the decision making process for patients pre-
senting with acute lower extremity ischemia.
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